Integris Medtech IPO Details
MAINBOARD
Integris Medtech IPO DRHP (Draft Red Herring Prospectus) has been SEBI Approval Received.
Offer for Sale consists of 2,16,74,531 shares (aggregating up to ₹0.00 Cr.).
The Lead Managers for Integris Medtech IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Axis Capital Ltd, IIFL Capital Services Ltd, ICICI Securities Ltd, Citigroup Global Markets India Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Integris Medtech Limited DRHP.
Integris Medtech IPO Details
Integris Medtech IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Integris Medtech IPO Reservation
Promoter Holding
Documents
Integris Medtech IPO Valuations
Integris Medtech Financial Information
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 4,019.62 | 3,641.34 | 2,989.20 | 2,553.87 |
| Total Income | 508.93 | 1,959.58 | 1,582.26 | 1,369.66 |
| Profit After Tax | 267.57 | 70.68 | -4.88 | -40.54 |
| EBITDA | 78.73 | 309.40 | 190.45 | 168.82 |
| NET Worth | 3,889.99 | 2,752.52 | 2,681.02 | 2,629.52 |
| Reserves and Surplus | 2,299.84 | 1,150.74 | 1,135.71 | 1,073.12 |
| Total Borrowing | 793.42 | 1,729.46 | 813.10 | 556.54 |
| Amount in ₹ Crore | ||||
About Integris Medtech IPO
Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.
Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments.
The company’s business is structured into two core divisions:
- Cardiovascular Devices – encompassing drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions.
- Laboratory Solutions – covering clinical, research, and industrial laboratory equipment, reagents, and consumables, along with services such as instrument installation, maintenance, and calibration through its BioCal™ brand.
Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors.
Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America.
As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.
Strength Of Integris Medtech IPO
Risk Of Integris Medtech IPO
Objectives Integris Medtech IPO
1. Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by:
2. The wholly-owned Subsidiaries, namely, Translumina Therapeutics Private Limited (“Translumina Therapeutics”), Transhealth Private Limited (“Transhealth”) ”) and HaleMed Medical Private Limited; and
3. The step-down Subsidiaries, namely, CPC Diagnostics Private Limited, Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd.
4. General corporate purposes
Company Contact Details
Integris Medtech Ltd.
1 st Floor
Metro Tower LSC
M.O.R Land, New Rajinder Nagar
North Delhi, New Delhi, 110060
Phone: +91 120 4531422
Email: investors@integrismedtech.com
Website: http://www.integrismedtech.com/
Registrar Contact Details
Integris Medtech IPO - FAQs
The Integris Medtech IPO is a MAINBOARD public issue comprising 0 equity shares with a face value of ₹1 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
Kfin Technologies Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.